Clinical Scorecard: Outcomes of Diabetes Remission Following LRYGBP With and Without Fundus Resection: Results from a Randomized Clinical Study

At a Glance

Key Highlights

• LRYGBP combined with gastric fundus resection may optimize antidiabetic effects by reducing ghrelin levels and enhancing glycemic control.
• GLP-1 is a potent incretin hormone increasing pancreatic beta-cell response and insulin secretion, crucial for T2DM remission.
• Randomized controlled trial with 24 patients showed no intraoperative complications and standardized surgical technique with longer operative time in fundus resection group.

Guideline-Based Recommendations

Diagnosis

• T2DM diagnosis based on ADA criteria: fasting glucose >126 mg/dl, OGTT impaired glucose values, HbA1c >6.5%, or use of antidiabetic medications.

Management

• Consider laparoscopic Roux-en-Y gastric bypass (LRYGBP) for patients with severe obesity and T2DM.
• Addition of gastric fundus resection to LRYGBP may enhance early glycemic improvement independently of weight loss.

Monitoring & Follow-up

• Monitor HbA1c levels at one-year postoperatively as primary outcome.
• Assess BMI, excess weight loss, glycemic parameters (glucose, C-peptide, insulin, insulinogenic index, HOMA-IR), and GI hormones (ghrelin, GLP-1, PYY) preoperatively and at 6 and 12 months postoperatively.

Risks

• Longer operative time (~18 minutes) associated with fundus resection modification.
• Exclude patients with type 1 diabetes, gestation, substance abuse, major depression, non-compliance, or prior altered GI anatomy.

Patient & Prescribing Data

Adults with severe obesity (BMI ≥40 kg/m2) and T2DM of less than 8 years duration.

Termination of antidiabetic medications 48 hours prior and GLP-1 analogues one week prior to surgery is recommended for accurate preoperative assessment.

Clinical Best Practices

• Perform all procedures laparoscopically by experienced surgeons to minimize complications.
• Create a small gastric pouch (~30 ml) with long biliopancreatic (200 cm) and alimentary limbs (150 cm) for LRYGBP.
• Standardize blood sampling protocols including fasting state and timing during OGTT for hormone and glycemic parameter measurement.
• Use validated ELISA kits for hormone assays and process samples uniformly to reduce variability.

References

• Clinical trial registration NCT05854875
• American Diabetes Association diagnostic criteria
• Helsinki Declaration 1964